Recent Investment Analysts’ Ratings Changes for Xencor (XNCR)

A number of research firms have changed their ratings and price targets for Xencor (NASDAQ: XNCR):

• 9/21/2026 – Xencor had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/21/2026 – Xencor had its price target raised by Bank of America Corporation from $20.00 to $26.00. They now have a “neutral” rating on the stock.
• 9/11/2026 – Xencor had its price target raised by Barclays PLC from $27.00 to $35.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Xencor had its price target raised by JPMorgan Chase & Co. from $14.00 to $21.00. They now have a “neutral” rating on the stock.
• 9/1/2026 – Xencor had its price target raised by Raymond James Financial, Inc. from $40.00 to $46.00. They now have a “strong-buy” rating on the stock.
• 8/8/2026 – Xencor was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/6/2026 – Xencor had its price target raised by Royal Bank Of Canada from $19.00 to $20.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Xencor had its price target raised by Wedbush from $26.00 to $30.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Xencor had its price target raised by Cantor Fitzgerald from $43.00 to $44.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Xencor had its “outperform” rating reaffirmed by Wedbush. They now have a $26.00 price target on the stock.

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies.